Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886309612> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2886309612 abstract "Objectives: To describe the clinical profiles, safety and efficacy endpoints, and response to cangrelor in US and non-US subgroups. Background: CHAMPION PHOENIX demonstrated superiority of cangrelor in reducing ischemic events at 48 hours in patients undergoing percutaneous coronary intervention (PCI) compared with clopidogrel. Methods: We analyzed all patients included in the modified intention-to-treat analysis in US (n=4,097; 37.4%) and non-US subgroups (n=6,845; 62.6%). Results: The US cohort was older and had higher rates of cardiovascular risk factors and prior cardiovascular procedures. US patients more frequently underwent PCI for stable angina (72.4% vs. 46.4%). Utilization of clopidogrel loading doses of 600mg and bivalirudin was also higher in US vs. non-US participants. At 48 hours, rates of the primary composite endpoint were lower in the cangrelor arm compared with the clopidogrel arm in US (4.5% vs. 6.4%; OR 0.71 [0.54-0.92]) and in non-US patients (4.8% vs. 5.6%; OR 0.85 [0.69-1.05]); interaction P=0.26 ( Table ). Similarly, rates of the key secondary endpoint, stent thrombosis, were reduced by cangrelor in both regions. Rates of GUSTO (Global Use of Strategies to Open Occluded Arteries)-defined severe bleeding were low and not significantly increased by cangrelor in either region. Conclusions: Despite broad differences in clinical profiles and indications for PCI by region in a large global cardiovascular clinical trial, cangrelor consistently reduced rates of ischemic endpoints compared with clopidogrel without an excess in severe bleeding in both US and non-US subgroups." @default.
- W2886309612 created "2018-08-22" @default.
- W2886309612 creator A5007026783 @default.
- W2886309612 creator A5010936003 @default.
- W2886309612 creator A5012209049 @default.
- W2886309612 creator A5026004870 @default.
- W2886309612 creator A5039432822 @default.
- W2886309612 creator A5046629853 @default.
- W2886309612 creator A5060370891 @default.
- W2886309612 creator A5061881316 @default.
- W2886309612 creator A5062843291 @default.
- W2886309612 creator A5065347832 @default.
- W2886309612 creator A5069820090 @default.
- W2886309612 creator A5086306721 @default.
- W2886309612 date "2015-11-10" @default.
- W2886309612 modified "2023-09-30" @default.
- W2886309612 title "Abstract 18632: Variation in Patient Profiles and Outcomes in US and non-US Subgroups of the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial" @default.
- W2886309612 doi "https://doi.org/10.1161/circ.132.suppl_3.18632" @default.
- W2886309612 hasPublicationYear "2015" @default.
- W2886309612 type Work @default.
- W2886309612 sameAs 2886309612 @default.
- W2886309612 citedByCount "0" @default.
- W2886309612 crossrefType "journal-article" @default.
- W2886309612 hasAuthorship W2886309612A5007026783 @default.
- W2886309612 hasAuthorship W2886309612A5010936003 @default.
- W2886309612 hasAuthorship W2886309612A5012209049 @default.
- W2886309612 hasAuthorship W2886309612A5026004870 @default.
- W2886309612 hasAuthorship W2886309612A5039432822 @default.
- W2886309612 hasAuthorship W2886309612A5046629853 @default.
- W2886309612 hasAuthorship W2886309612A5060370891 @default.
- W2886309612 hasAuthorship W2886309612A5061881316 @default.
- W2886309612 hasAuthorship W2886309612A5062843291 @default.
- W2886309612 hasAuthorship W2886309612A5065347832 @default.
- W2886309612 hasAuthorship W2886309612A5069820090 @default.
- W2886309612 hasAuthorship W2886309612A5086306721 @default.
- W2886309612 hasConcept C126322002 @default.
- W2886309612 hasConcept C164705383 @default.
- W2886309612 hasConcept C203092338 @default.
- W2886309612 hasConcept C2776708134 @default.
- W2886309612 hasConcept C2777565915 @default.
- W2886309612 hasConcept C2777628954 @default.
- W2886309612 hasConcept C2777849778 @default.
- W2886309612 hasConcept C2780400711 @default.
- W2886309612 hasConcept C45393284 @default.
- W2886309612 hasConcept C49059817 @default.
- W2886309612 hasConcept C500558357 @default.
- W2886309612 hasConcept C535046627 @default.
- W2886309612 hasConcept C71924100 @default.
- W2886309612 hasConceptScore W2886309612C126322002 @default.
- W2886309612 hasConceptScore W2886309612C164705383 @default.
- W2886309612 hasConceptScore W2886309612C203092338 @default.
- W2886309612 hasConceptScore W2886309612C2776708134 @default.
- W2886309612 hasConceptScore W2886309612C2777565915 @default.
- W2886309612 hasConceptScore W2886309612C2777628954 @default.
- W2886309612 hasConceptScore W2886309612C2777849778 @default.
- W2886309612 hasConceptScore W2886309612C2780400711 @default.
- W2886309612 hasConceptScore W2886309612C45393284 @default.
- W2886309612 hasConceptScore W2886309612C49059817 @default.
- W2886309612 hasConceptScore W2886309612C500558357 @default.
- W2886309612 hasConceptScore W2886309612C535046627 @default.
- W2886309612 hasConceptScore W2886309612C71924100 @default.
- W2886309612 hasIssue "suppl_3" @default.
- W2886309612 hasLocation W28863096121 @default.
- W2886309612 hasOpenAccess W2886309612 @default.
- W2886309612 hasPrimaryLocation W28863096121 @default.
- W2886309612 hasRelatedWork W2043535440 @default.
- W2886309612 hasRelatedWork W2088680944 @default.
- W2886309612 hasRelatedWork W2551205994 @default.
- W2886309612 hasRelatedWork W2786158905 @default.
- W2886309612 hasRelatedWork W3007497445 @default.
- W2886309612 hasRelatedWork W3125666540 @default.
- W2886309612 hasRelatedWork W3189490423 @default.
- W2886309612 hasRelatedWork W4311497569 @default.
- W2886309612 hasRelatedWork W4311737800 @default.
- W2886309612 hasRelatedWork W4313339810 @default.
- W2886309612 hasVolume "132" @default.
- W2886309612 isParatext "false" @default.
- W2886309612 isRetracted "false" @default.
- W2886309612 magId "2886309612" @default.
- W2886309612 workType "article" @default.